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Abstract 
Purpose: The DIANA study aimed to evaluate how often antimicrobial de‑escalation (ADE) of empirical treatment is 
performed in the intensive care unit (ICU) and to estimate the effect of ADE on clinical cure on day 7 following treat‑
ment initiation.
Methods: Adult ICU patients receiving empirical antimicrobial therapy for bacterial infection were studied in a pro‑
spective observational study from October 2016 until May 2018. ADE was defined as (1) discontinuation of an antimi‑
crobial in case of empirical combination therapy or (2) replacement of an antimicrobial with the intention to narrow 
the antimicrobial spectrum, within the first 3 days of therapy. Inverse probability (IP) weighting was used to account 
for time‑varying confounding when estimating the effect of ADE on clinical cure.
Results: Overall, 1495 patients from 152 ICUs in 28 countries were studied. Combination therapy was prescribed in 
50%, and carbapenems were prescribed in 26% of patients. Empirical therapy underwent ADE, no change and change 
other than ADE within the first 3 days in 16%, 63% and 22%, respectively. Unadjusted mortality at day 28 was 15.8% in 
the ADE cohort and 19.4% in patients with no change [p = 0.27; RR 0.83 (95% CI 0.60–1.14)]. The IP‑weighted relative 
risk estimate for clinical cure comparing ADE with no‑ADE patients (no change or change other than ADE) was 1.37 
(95% CI 1.14–1.64).
Conclusion: ADE was infrequently applied in critically ill‑infected patients. The observational effect estimate on clini‑
cal cure suggested no deleterious impact of ADE compared to no‑ADE. However, residual confounding is likely.
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Introduction
Antimicrobial de-escalation (ADE) is a treatment strat-
egy pursuing early adequate antimicrobial therapy as 
well as a reduction in the overall use of broad-spectrum 
agents, with the aim to contain subsequent emergence 
of multidrug resistance [1–4]. De-escalation may be 
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achieved through replacement of a broad-spectrum 
antimicrobial by an antimicrobial agent with a nar-
rower spectrum or a lower ecological impact or by dis-
continuation of one or more antimicrobials of empirical 
combination therapy [4–7]. Internationally, ADE is rec-
ognized as a key component of antimicrobial steward-
ship [8–10].
Information on how often ADE is performed in every-
day practice on a world-wide scale is lacking. Whereas 
the extended prevalence of infection in intensive care 
studies provided more insight in the global epidemiol-
ogy of infections and antimicrobial use in critically ill 
patients; international studies mapping complete anti-
microbial treatment courses in intensive care unit (ICU) 
patients are unavailable at present [11, 12].
Many observational studies and few randomized con-
trolled trials (RCT) evaluated ADE and the impact 
thereof on patient outcome. RCTs have been unable to 
show convincing evidence that ADE is definitely safe, 
while systematic reviews have indicated a positive influ-
ence of ADE on mortality [4, 13–15]. Controversies 
regarding the safety of ADE nonetheless still exist as 
various definitions were used and antimicrobials were 
predominantly de-escalated in patients with microbiolog-
ically confirmed infections and a favorable clinical course. 
As such, observational studies are prone to bias [16].
The aims of the DetermInants of Antimicrobial use 
aNd de-escalAtion in critical care (DIANA) study were 
to determine how often ADE of an empirically pre-
scribed therapy is performed in an ICU population and 
to estimate the effect of ADE on clinical cure on day 
7 following initiation of empirical therapy, while ade-
quately accounting for drivers of ADE that may evolve 
over time and also affect clinical outcome.
Methods
The DIANA study was a multicenter international obser-
vational cohort study investigating adult critically ill 
patients receiving empirical antimicrobial therapy for 
suspected or confirmed bacterial infections in the ICU. 
An international steering committee was established in 
2015 and consisted of members of the European Society 
of Intensive Care Medicine (ESICM) Infection section. A 
network of national coordinators recruited investigators, 
coordinated study participation and monitored local eth-
ics committee approval at each participating center. The 
Ghent University Hospital Ethics Committee approved 
the study (registration number B670201629297). The 
study was not funded and participation was volun-
tary. The trial was registered in ClinicalTrials.gov 
(NCT02920463).
Participants
Patients were eligible for inclusion if they were 18 years or 
older and admitted to an ICU with an anticipated need of 
at least 48 h of ICU support. An empirical antimicrobial 
therapy had to be initiated in the ICU or no more than 24 h 
prior to ICU admission to treat a community-, healthcare-, 
hospital- or ICU-acquired bacterial infection. Antimicro-
bial therapy was defined as empirical in case the causative 
pathogen and susceptibility pattern were unidentified at 
the time of initiation of the antimicrobials. Patients could 
be included once. Informed consent was either obtained or 
waived according to local ethics committee requirements. 
Participating ICUs were asked to include all consecutive 
patients who were eligible during a convenient 2-week 
period, or an extended time period to provide the oppor-
tunity to include 10 patients. Patients could be included 
from October 2016 until May 2018.
Data collection
Data were submitted through an Electronic Data Capture 
platform (CASTOR™) [17]. Patient, infection and anti-
microbial treatment-related data were collected from the 
day of study inclusion (day 0), defined as the start date 
of empirical antimicrobial therapy, until day 28. No inter-
ventions or measurements other than those that were 
standard of care were performed.
Patient-related data included: age; sex; co-morbidities; 
previous antimicrobial and hospital exposure; admission 
category and diagnosis. Severity of illness was evaluated 
using Acute Physiology And Chronic Health Evaluation 
(APACHE) II and Simplified Acute Physiology Score 
(SAPS) II on the day of ICU admission; Sequential Organ 
Failure Assessment (SOFA) scores were collected on the 
day of ICU admission, day 0 and day 3 (online supple-
ment 1). The presence (i.e., multi-drug-resistant (MDR) 
pathogens present on ICU admission and/or detected 
before day 2) or emergence (i.e., MDR pathogens detected 
between day 2 and day 28 and not present before) of 
MDR pathogens was evaluated. Multi-drug resistance 
was defined as a pathogen producing extended-spectrum 
beta-lactamase (ESBL) or carbapenemase, Stenotropho-
monas maltophilia, methicillin-resistant Staphylococ-
cus aureus, vancomycin-resistant Enterococcus sp., or a 
Take‑home message 
ADE was performed within 3 days following empirical prescription 
in only 16% of critically ill‑infected patients, despite the fact that 
half of the empirical prescriptions consisted of combination therapy 
and one‑quarter contained a carbapenem. The observational effect 
estimate on clinical cure suggested no deleterious impact of ADE 
compared to no‑ADE; however, residual confounding is likely to be 
present.
pathogen resistant to 3 or more antimicrobial classes in 
accordance with the publication of Magiorakos et al. [18]. 
MDR-tables were constructed as guidance (online sup-
plement 2). The need for supportive therapy, number of 
days in the ICU and hospital, ICU and hospital mortality 
were recorded until day 28. The clinical response of the 
patient for the initial infection was assessed by the treat-
ing clinician on day 7. Clinical cure was defined as sur-
vival and resolution of all signs and symptoms related to 
the infection.
Infection-related data included: source, need for source 
control, causative pathogens and susceptibility patterns. 
Antimicrobial treatment-related data included: type 
and timing of all antimicrobial agents that were initi-
ated. Indications for stopping, switching or addition of 
an agent were recorded. Infection relapse, defined as an 
infection with the same causative microorganism and 
source that occurred after discontinuation of all antimi-
crobial agents for the primary infection, was evaluated 
until day 28. Additional antimicrobial therapy following 
study inclusion and antimicrobial-free days were assessed 
at 28 days following inclusion.
In addition, each participating ICU had to provide 
information on local antimicrobial resistance, organiza-
tional aspects of the ICU and presence of antimicrobial 
stewardship interventions in the ICU, e.g., multidisci-
plinary staff meetings and local antimicrobial treatment 
guidelines.
Data management
Data monitoring was performed by two investigators 
(LDB, KDS)
Antimicrobial treatment courses were classified based 
on the first modification of therapy (or the absence 
thereof ) that took place between day 0 and day 3 as: 
“no change” (empirical therapy was maintained without 
modification between day 0 and day 3); “ADE” or “other 
change”.
For the current analysis, ADE was defined as: (1) discon-
tinuation of one or more antimicrobials of the empirical 
combination therapy which were considered by the treat-
ing physician to be not (or no longer) necessary for treat-
ment of the infection within the first 3 days of initiation 
of empirical therapy (e.g., stopping vancomycin on day 2 
following initial treatment with piperacillin-tazobactam 
combined with vancomycin); (2) replacement of an anti-
microbial agent by another drug with the intention of 
the treating physician to narrow the spectrum of activity 
within the first 3 days of empirical therapy (e.g., replace-
ment of meropenem by amoxicillin-clavulanate on day 2). 
In addition, physicians were asked to justify these deci-
sions and specify the reason for treatment modification.
“Other change” was defined as: (1) the addition or 
replacement of an antimicrobial agent by the treating cli-
nician within the first 3 days of empirical therapy, based 
on clinical deterioration or lack of clinical improve-
ment, the presence of resistant causative and/or colo-
nizing pathogens and/or presumed inadequacy of the 
initial treatment (e.g., not concordant with guidelines); 
(2) replacement of an antimicrobial agent within the 
first 3  days of empirical therapy due to side-effects of 
antimicrobials.
Statistical analysis
Frequencies (percentages) are reported as descriptive 
summary statistics for categorical variables and medians 
and interquartile range (IQR) (25th to 75th percentile) for 
continuous variables. Distributional differences for cat-
egorical patient outcomes were evaluated using a Pearson 
Chi-squared test or Fisher’s exact test when appropriate. 
The Mann–Whitney U test was used for comparison of 
non-normally distributed continuous outcomes. Risk 
ratios were reported for binary variables, along with 95% 
confidence intervals (CIs). Unadjusted outcome analy-
ses were performed comparing ADE and “no change” 
patients, and “other change” and “no change” patients.
Two primary outcome measures were defined: The 
incidence of ADE and clinical cure on day 7. Statisti-
cal analysis was tailored so as to emulate a hypothetical 
randomized trial to estimate the effect of ADE on clini-
cal cure on day 7 (see online supplement 3 for additional 
statistical information) [19–23]. Inverse probability (IP) 
weighting was used to control for time-varying con-
founding that might affect both the decision of ADE on 
each day within the considered 4-day time period and 
clinical cure on day 7. Selection of these confounders was 
based on subject matter knowledge by means of a Delphi 
approach within the steering committee [24, 25]. Immu-
nosuppression status, delta SOFA (defined as SOFA day 
0 minus SOFA day 3), need and effectiveness of source 
control and identification of causative microbiology 
were selected by the panel and included in the analy-
sis. Susceptibility pattern of the causative pathogen was 
selected but not included in the analysis due to incom-
plete timing-related data. Two additional covariates were 
included: (1) the continent where the ICU was located to 
account for missing data in certain regions; (2) the num-
ber of empirical agents to enable multiple subgroup and 
sensitivity analyses. Sensitivity analyses entailed inclu-
sion of SOFA day 0, inappropriate empirical therapy and 
MDR colonization as covariate. The results are presented 
as absolute weighted risks, relative risk and 95% CI.
Post hoc power and sample size calculations using the 
IP weighted analysis were performed.
Statistical analysis was performed using R Statistical 
Software (version 3.4.2; The R Foundation for Statistical 
Computing. Vienna, Austria) using the packages geepack, 
ipw, multcomp and splines [26–30].
The Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) guidelines for report-
ing of observational studies and the recommendations to 
optimize reporting of epidemiological studies on antimi-
crobial resistance and informing improvement in antimi-
crobial stewardship (STROBE-AMS) were followed [31, 
32].
Results
Participating intensive care units
A total of 152 ICUs in 28 countries participated; 48% 
in Europe, 38% in Asia, 9% in America and 5% in Aus-
tralia and New-Zealand (online supplement 4). Ninety 
percent of participating centers were teaching hospitals, 
81% were mixed ICUs and 76% worked in a closed ICU 
organization. Infectious disease specialists, microbiolo-
gists and clinical pharmacists joined regular multidisci-
plinary staff meetings in 28%, 24% and 22% of centers, 
respectively. Local ADE guidelines were used in 25.4% of 
centers. Baseline methicillin resistance of the S. aureus 
isolates was 10% (IQR 3–26) in the participating ICUs; 
vancomycin resistance of the enterococcus species iso-
lates 0% (IQR 0–3). ESBL production was reported in 
11% (IQR 5–21) of enterobacteriaceae isolates, whereas 
carbapenemase production was reported in 1% (IQR 
0–5). Detailed center characteristics are presented in 
online supplement 5.
Overall patient, infection and treatment characteristics
A total of 1495 patients were available for analysis 
(online supplement 6). Median age was 65 (IQR 51–75) 
years, 61.5% were male and 66.6% were medical admis-
sions. Patients were colonized with MDR pathogens 
prior to initiation of empirical antimicrobial therapy 
in 11.5%. Patient characteristics are detailed in Table 1. 
Infection and treatment characteristics are described 
in Table 2. Combination therapy was prescribed in 50% 
of empirical courses. The most frequently prescribed 
agents were anti-pseudomonal penicillins in combina-
tion with a beta-lactamase inhibitor, carbapenems and 
third-generation cephalosporins in 29.6%, 26% and 
19.3% of patients, respectively (Table  3). Infections 
were microbiologically confirmed in 55.8%. Empiri-
cal therapy was considered inappropriate by the treat-
ing clinician based on the susceptibility pattern of the 
causative pathogen and triggered treatment modifi-
cation in 10% of patients. Median number of days in 
the ICU and hospital following the onset of the infec-
tion were 8 (IQR 5–18) in ICU survivors and 26 (IQR 
13–28) days in hospital survivors, respectively. The 
28-day mortality rate was 19.8%.  
Proportion of ADE patients
During the first 3 days, empirical antimicrobial therapy 
was de-escalated in 16% (240/1495) and not changed 
in 63% (934/1495). In 22% (321/1495) of patients, 
another treatment change was performed. Five per-
cent (75/1495) of patients died during the first 3 days of 
therapy. A detailed description of the treatment modi-
fications between day 0 and day 7 is available in online 
supplement 7.
Description of ADE
ADE consisted mainly of discontinuation of one or more 
components of combination therapy [52% (125/240)], 
whereas 35% (84/240) of ADE consisted of replace-
ment of an antimicrobial agent by another drug. Both 
ADE approaches were applied in 13% (31/240) of ADE 
patients. The absence of microbiological confirmation 
and dual coverage of causative pathogens were the most 
prevalent incentives for discontinuation of a component 
of combination therapy. ADE in the form of replace-
ment was mainly based on identification and suscepti-
bility pattern of the causative pathogen (Table  4). The 
antimicrobial classes that were discontinued most often 
as components of a combination therapy were glycopep-
tides (n = 46), aminoglycosides (n = 43) and macrolides 
(n = 29). The most frequently performed switches in the 
setting of ADE were: piperacillin-tazobactam to a third-
generation cephalosporin and piperacillin-tazobactam to 
penicillin in combination with a beta-lactamase inhibitor. 
De-escalated beta-lactam prescriptions complied with 
the ranking developed by Weiss et  al. in 91% (69/76) of 
the patients [33]. Online supplement 8 contains detailed 
information on ADE practices. ADE took place on day 0, 
day 1, day 2 and day 3 in 21%, 30%, 25% and 25% of ADE 
patients, respectively.
Patient, infection and treatment characteristics associated 
with ADE
The distribution of sex, age, pre-existing co-morbidities 
and immunosuppression status of patients was compa-
rable in the ADE and “no change” cohort. Prior health-
care exposure occurred in 53.3% of ADE patients and 
in 44.0% of “no change” patients. Differences in antimi-
crobial treatment exposure between hospital admission 
and empirical treatment initiation and pre-existing MDR 
colonization between the ADE and “no change” cohorts 
were small (52.5% vs. 49.9%, and 8.8% vs. 10.5%, respec-
tively) (Table 1).
Severity of illness at ICU admission, SOFA day 0 and 
SOFA day 3 had comparable distributions in the ADE and 
Table 1 Patient characteristics
Results are shown as n (%) or median [IQR] where applicable
ADE antimicrobial de-escalation, APACHE acute physiology and chronic health evaluation, ICU intensive care unit, MDR multidrug-resistant, SAPS simplified acute 
physiology score, SOFA sequential organ failure assessment
a Multiple admission diagnoses may be assigned to one patient
b Hospitalization for ≥ 2 days in the 12 months prior to study inclusion, antimicrobial exposure in the last 3 months prior to study inclusion, resident in a nursing 
home or long-term care facility, receiving chronic hemodialysis or receiving invasive procedures (at home or in an outpatient clinic) in the last 30 days prior to study 
inclusion
c Congenital immunodeficiency, neutropenia (absolute neutrophil count < 1000 neutrophils/μl), patient receiving corticosteroid treatment (prednisolone or 
equivalent > 0.5 mg/kg/day for > 3 months prior to study inclusion), solid organ transplant patient receiving immunosuppressive treatment, bone marrow transplant 
patient receiving immunosuppressive treatment, administration of chemotherapy within 1 year prior to study inclusion, administration of radiotherapy within 1 year 
prior to study inclusion, patient with autoimmune disease receiving immunosuppressive treatment, HIV or AIDS
d Defined as all MDR pathogens presumed to be already present on ICU admission, within 1 year prior to study inclusion combined with all MDR pathogens not 





n = 934; 
62.5%
ADE
n = 240; 16.1%
Other change
n = 321; 21.5%
Age (years) 65 [51–75] 66 [51–75] 65 [54–74] 65 [51–76]
Male sex 919 (61.5%) 561 (60%) 152 (63.3%) 206 (64.2%)
Apache II score on ICU admission 19 [14–25] 18 [13–24] 19 [15–27] 20 [14–25]
SAPS II score on ICU admission 43 [31–57] 42 [30–56] 42 [32–56] 43 [33–59]
SOFA score on ICU admission 7 [4–10] 7 [4–10] 7 [5–10] 7 [5–10]
Hospitalization duration prior to initiation of empirical antimicrobials (days) 1 [0–5] 1 [0–5] 1 [0–3] 1 [0–6]
Antimicrobial exposure between day of hospitalization and initiation of empirical 
antimicrobials
775 (51.8%) 466 (49.9%) 126 (52.5%) 183 (57%)
Admission category
 Medical 996 (66.6%) 609 (65.2%) 175 (72.9%) 212 (66%)
 Surgical 425 (28.4%) 275 (29.4%) 55 (22.9%) 95 (29.6%)
 Trauma 70 (4.7%) 47 (5%) 9 (3.8%) 14 (4.4%)
 Burns 3 (0.2%) 3 (0.3%) 0 0
Admission  diagnosisa
 Cardiovascular/vascular 300 (20.1%) 187 (20%) 51 (21.3%) 62 (19.3%)
 Digestive 351 (23.5%) 228 (24.4%) 48 (20%) 75 (23.4%)
 Hematological 49 (3.3%) 32 (3.4%) 8 (3.3%) 9 (2.8%)
 Metabolic 99 (6.6%) 65 (7%) 11 (4.6%) 23 (7.2%)
 Neurological 298 (19.9%) 204 (21.8%) 41 (17.1%) 53 (16.5%)
 Pregnancy related 14 (0.9%) 9 (1%) 3 (1.3%) 2 (0.6%)
 Renal/genito‑urinary 209 (14%) 111 (11.9%) 42 (17.5%) 56 (17.4%)
 Respiratory 584 (39.1%) 364 (39%) 95 (39.6%) 125 (39%)
 Trauma and skin 151 (10.1%) 86 (9.2%) 27 (11.3%) 38 (11.8%)
 Other 50 (3.3%) 32 (3.4%) 6 (2.5%) 12 (3.7%)
Co‑morbidities 1065 (71.2%) 658 (70.4%) 179 (74.6%) 228 (1%)
 Chronic pulmonary disease 279 (18.7%) 163 (17.5%) 49 (20.4%) 67 (20.9%)
 Chronic hepatic disease 105 (7%) 61 (6.5%) 19 (7.9%) 25 (7.8%)
 Chronic renal failure 185 (12.4%) 112 (12%) 30 (12.5%) 43 (13.4%)
 Diabetes mellitus 372 (24.9%) 214 (22.9%) 69 (28.8%) 89 (27.7%)
 Cardiovascular disease 567 (37.9%) 353 (37.8%) 98 (40.8%) 116 (6.1%)
 Solid tumor 193 (12.9%) 107 (11.5%) 36 (15%) 50 (15.6%)
 Hematologic malignancy 66 (4.4%) 36 (3.9%) 16 (6.7%) 14 (4.4%)
 Cerebrovascular disease 153 (10.2%) 103 (11%) 19 (7.9%) 31 (9.7%)
 No data available on co‑morbidities 51 (3.4%) 33 (3.5%) 2 (0.8%) 16 (5%)
Healthcare  exposuresb 691 (46.2%) 411 (44%) 128 (53.3%) 152 (47.4%)
Immunosuppression  statusc 240 (16%) 137 (14.7%) 42 (17.5%) 61 (19%)
Colonization with MDR pathogens prior to initiation of empirical  antimicrobialsd 172 (11.5%) 98 (10.5%) 21 (8.8%) 53 (16.5%)
“no change” cohort. Septic shock at presentation was more 
prevalent in ADE compared to “no change” patients (29.6% 
vs. 21.5%, respectively). ADE patients had higher rates of 
microbiological confirmation (74.2% vs. 48%, respectively), 
bacteremia (32.5% vs. 14.1%, respectively) and need for 
source control (27.1% vs. 20.6%, respectively) compared to 
“no change” patients. Online supplements 9 and 10 contain 
details related to causative microbiology and resistance 
patterns. The use of empirical antimicrobial combination 
therapy differed between both strategies [82.1% (ADE) vs. 
42.4% (“no change”)], but the overall treatment durations 
were comparable (10 days (IQR 7–15) in ADE cohort vs. 
9 days (IQR 6–15) in “no change” cohort) (Table 2).
Outcome
Delta SOFA and rate of clinical cure on day 7 were higher 
in ADE compared to “no change” patients [2 (IQR 0–4) 
vs. 1 (IQR 0–3); p < 0.001 and 57.9% vs. 42.7%; RR 1.34 
(1.18–1.52); p < 0.001, respectively]. Emergence of MDR 
was 7.5% in ADE patients compared to 11.9% in “no 
change” patients (RR 0.63 (0.39–1.01); p = 0.06,). Infec-
tion relapse rate and antimicrobial-free days at day 28 
Table 2 Infection and treatment characteristics
Results are shown as n (%) or median [IQR] where applicable
ADE antimicrobial de-escalation, SOFA sequential organ failure assessment
a Multiple infection diagnoses may be assigned to one patient; infection focusses with an overall frequency of less than 3% were included in the ‘other infection 
diagnosis’ category and include: bone and joint infections; central nervous system infections; neutropenic fever; other unspecified infections





n = 934; 62.5%
ADE
n = 240; 16.1%
Other change
n = 321; 
21.5%
Infection characteristics
Source of  infectiona
 Abdominal 272 (18.2%) 170 (18.2%) 37 (15.4%) 65 (20.2%)
 Cardiovascular and intravascular 50 (3.3%) 27 (2.9%) 11 (4.6%) 12 (3.7%)
 Catheter‑related 46 (3.1%) 25 (2.7%) 5 (2.1%) 16 (5%)
 Respiratory 717 (48%) 464 (49.7%) 106 (44.2%) 147 (45.8%)
 Skin 107 (7.2%) 54 (5.8%) 23 (9.6%) 30 (9.3%)
 Uro‑genital 149 (10%) 76 (8.1%) 34 (14.2%) 39 (12.1%)
 Other 117 (7.8%) 71 (7.6%) 22 (9.2%) 24 (7.5%)
 Unknown 171 (11.4%) 119 (12.7%) 22 (9.2%) 30 (9.3%)
Diagnostic certainty (range 1–10) 10 [8–10] 10 [8–10] 10 [9–10] 10 [8–10]
Septic shock 334 (22.3%) 201 (21.5%) 71 (29.6%) 62 (19.3%)
SOFA day 0 7 [4–10] 7 [4–10] 7 [510] 7 [5–9.5]
SOFA day  3b 5 [3–8] 5 [38] 4 [2–8] 6 [4–9]
Microbiologically documented infection 834 (55.8%) 448 (48%) 178 (74.2%) 208 (64.8%)
Polymicrobial infection 275 (18.4%) 162 (17.3%) 39 (16.3%) 74 (23.1%)
Bacteremia 293 (19.6%) 132 (14.1%) 78 (32.5%) 83 (25.9%)
Need for source control 349 (23.3%) 192 (20.6%) 65 (27.1%) 92 (28.7%)
Effectiveness of source control on day 3 (n = number of 
patients who need source control)
214/349 (61.3%) 116/192 (60.4%) 49/65 (75.4%) 49/92 (53.2%)
Treatment characteristics
Empirical antimicrobial prescription
 Monotherapy 753 (50.4%) 538 (57.6%) 43 (17.9%) 172 (53.6%)
 Combination therapy 742 (49.6%) 396 (42.4%) 197 (82.1%) 149 (46.4%)
  2 Antimicrobial agents 519 285 119 115
  3 Antimicrobial agents 181 95 59 27
  4 Antimicrobial agents 38 15 18 5
  5 Antimicrobial agents 4 1 1 2
Duration of treatment for the infection under study (days) 10 [7–16] 9 [6–15] 10 [7–15] 12 [7–17]
Inappropriate empirical antimicrobial  prescriptionb 151 (10%) 67 (7.2%) 10 (4.2%) 74 (23.1%)
Table 3 Empirical antimicrobial therapy
Overall use Treatment
Total n = 1495 No change n = 934 ADE n = 240 Other change n = 321
Antipseudomonal penicillins + β‑lactamase 
inhibitor
442 (29.6%) 265 (28.4%) 91 (37.9%) 86 (26.8%)
Carbapenems 389 (26%) 248 (26.6%) 65 (27.1%) 76 (23.7%)
Third‑generation cephalosporins 289 (19.3%) 170 (18.2%) 57 (23.8%) 62 (19.3%)
Glycopeptides 258 (17.3%) 145 (15.5%) 72 (30%) 41 (12.8%)
Penicillins + β‑lactamase inhibitor 202 (13.5%) 138 (14.8%) 24 (10%) 40 (12.5%)
Fluoroquinolones 153 (10.2%) 89 (9.5%) 26 (10.8%) 38 (11.8%)
Macrolides 119 (8%) 54 (5.8%) 41 (17.1%) 24 (7.5%)
Aminoglycosides 110 (7.4%) 39 (4.2%) 52 (21.7%) 19 (5.9%)
Nitroimidazoles 86 (5.8%) 41 (4.4%) 21 (8.8%) 24 (7.5%)
Clindamycin 75 (5%) 49 (5.2%) 12 (5%) 14 (4.4%)
Linezolid 69 (4.6%) 40 (4.3%) 17 (7.1%) 12 (3.7%)
Penicillins 40 (2.7%) 15 (1.6%) 15 (6.3%) 10 (3.1%)
Fourth‑generation cephalosporins 36 (2.4%) 20 (2.1%) 9 (3.8%) 7 (2.2%)
Azoles 36 (2.4%) 22 (2.4%) 3 (1.3%) 11 (3.4%)
Echinocandins 36 (2.4%) 25 (2.7%) 5 (2.1%) 6 (1.9%)
Second‑generation cephalosporins 28 (1.9%) 15 (1.6%) 7 (2.9%) 6 (1.9%)
First‑generation cephalosporins 24 (1.6%) 12 (1.3%) 2 (0.8%) 10 (3.1%)
Tetracyclines 22 (1.5%) 13 (1.4%) 2 (0.8%) 7 (2.2%)
Tigecycline 22 (1.5%) 13 (1.4%) 5 (2.1%) 4 (1.2%)
Polymyxins 19 (1.3%) 9 (1%) 3 (1.3%) 7 (2.2%)
Folate pathway inhibitors 18 (1.2%) 13 (1.4%) 1 (0.4%) 4 (1.2%)
Daptomycin 10 (0.7%) 7 (0.7%) 1 (0.4%) 2 (0.6%)
Polyenes 4 (0.3%) 3 (0.3%) 1 (0.4%) 0
Fosfomycin 3 (0.2%) 2 (0.2%) 0 1 (0.3%)
Rifampin 3 (0.2%) 1 (0.1%) 2 (0.8%) 0
Fifth‑generation cephalosporins 1 (0.07%) 0 1 (0.4%) 0
Antifungal antimetabolites 1 (0.07%) 1 (0.1%) 0 0
Monobactams 1 (0.07%) 1 (0.1%) 0 0
Monotherapy—top 10 n = 753 n = 538 n = 43 n = 172
Antipseudomonal penicillins + β‑lactamase 
inhibitor
234 (31.1%) 165 (30.7%) 18 (41.9%) 51 (29.7%)
Carbapenems 159 (21.1%) 112 (20.8%) 12 (27.9%) 35 (20.3%)
Penicillins + β‑lactamase inhibitor 130 (17.3%) 102 (19%) 4 (9.3%) 24 (14%)
Third‑generation cephalosporins 89 (11.8%) 64 (11.9%) 4 (9.3%) 21 (12.2%)
Fluoroquinolones 48 (6.4%) 35 (6.5%) 1 (2.3%) 12 (7%)
Glycopeptides 16 (2.1%) 11 (2%) 1 (2.3%) 4 (2.3%)
First‑generation cephalosporins 16 (2.1%) 9 (1.7%) 1 (2.3%) 6 (3.5%)
Second‑generation cephalosporins 13 (1.7%) 8 (1.5%) 1 (2.3%) 4 (2.3%)
Fourth‑generation cephalosporins 12 (1.6%) 9 (1.7%) 1 (2.3%) 2 (1.2%)
Tetracyclines 6 (0.8%) 2 (0.4%) 0 4 (2.3%)
Combination therapy—top 10 n = 742 n = 396 n = 197 n = 149
Glycopeptides 242 (32.6%) 134 (33.8%) 71 (36%) 37 (24.8%)
Carbapenems 230 (31%) 136 (34.3%) 53 (26.9%) 41 (27.5%)
Antipseudomonal penicillins + β‑lactamase 
inhibitor
208 (28%) 100 (25.3%) 73 (37.1%) 35 (23.5%)
Third‑generation cephalosporins 200 (27%) 106 (26.8%) 53 (26.9%) 41 (27.5%)
Macrolides 114 (15.4%) 49 (12.4%) 41 (20.8%) 24 (16.1%)
were comparable in both treatment groups. Both median 
number ICU and hospital days were smaller in ADE than 
in “no change” patients [7  days (IQR 4–12) vs. 9  days 
(IQR 5–19); p < 0.001 and 19 days (IQR 10–28) vs. 27 days 
(IQR 14–28); p < 0.001, respectively]. Mortality at day 28 
was 15.8% in ADE and 19.4% in “no change” patients (RR 
0.83 (0.6–1.14); p = 0.27,). Details on patient outcome are 
described in Table 5.
Analysis of clinical cure in ADE patients using inverse 
probability weighting
The estimated relative risk of survival and clinical cure, 
survival without clinical cure and mortality on day 7 in 
ADE patients versus patients in whom ADE was not per-
formed on day 3 or earlier were 1.37 (95% CI 1.14–1.64), 
0.66 (95% CI 0.47–0.92) and 1.32 (95% CI 0.95–1.83), 
respectively. IP weighted risks and detailed results of 
subgroup and sensitivity analyses can be found in online 
supplement 11. Post hoc power and sample size calcula-
tions are available in online supplement 12.
Discussion
In this study, investigating empirical antimicrobial ther-
apy for patients with bacterial infections in the ICU, we 
found that ADE was infrequently applied, despite the 
fact that combination therapy was prescribed in half of 
the patients and one-quarter of prescriptions contained 
a carbapenem. Our observational effect estimate of ADE 
on clinical cure suggested that ADE performed within 
3  days following empirical prescription was not worse 
compared to no-ADE after adjustment for potential 
bias and confounding. However, residual confounding 
remains possible.
Previous studies reported ADE rates between 25 and 
81% [4, 34]. Studies with higher percentages of ADE often 
included patients with lower severity of illness compared 
to our study or focused on patients in whom ADE was 
possible due to the broadness of the empirical spectrum 
and the susceptibility pattern of the causative pathogens 
[4, 35]. Other studies included only patients with specific 
types of infections or pathogens [36–38]. These were 
usually single-center studies, conducted in centers with 
a special interest in antimicrobial stewardship. Instead, 
we studied ICU patients and included all empirical anti-
microbial therapies, independent of culture results, and 
therefore provide a more realistic picture of ADE in rou-
tine clinical practice.
Table 3 (continued)
Combination therapy—top 10 n = 742 n = 396 n = 197 n = 149
Aminoglycosides 107 (14.4%) 37 (9.3%) 52 (26.4%) 18 (12.1%)
Fluoroquinolones 105 (14.2%) 54 (13.6%) 25 (12.7%) 26 (17.4%)
Nitroimidazoles 84 (11.3%) 41 (10.4%) 21 (10.7%) 22 (14.8%)
Penicillins + β‑lactamase inhibitor 72 (9.7%) 36 (9.1%) 20 (10.2%) 16 (10.7%)
Clindamycin 72 (9.7%) 46 (11.6%) 12 (6.1%) 14 (9.4%)
Table 4 Motivation for ADE
ADE antimicrobial de-escalation
N (%)
Replacement of an antimicrobial agent by another drug with the intention to narrow the spectrum of activity
(115 ADE treatment courses) (multiple answers possible)
Gram’s stain results 13/115 (11.3)
Rapid polymerase chain reaction technology 3/115 (2.6)
Identification of the causative pathogen 67/115 (58.3)
Susceptibility pattern of the causative pathogen 54/115 (47)
Negative culture results 10/115 (8.7)
Improvement in organ function 14/115 (12.2)
Improvement in inflammation biomarkers 11/115 (9.6)
Better compliance with local guidelines 11/115 (9.6)
Discontinuation of one or more antimicrobials of the empirical combination therapy which were considered by the treating physician 
to be not (or no longer) necessary
(156 ADE treatment courses) (only one answer possible)
In case of microbiologically confirmed infection, causative pathogen is covered by concomitant antimicrobial therapy 67/156 (42.9)
In case of microbiologically confirmed infection, causative pathogen(s) is not covered by this antibacterial or antifungal agent 30/156 (19.2)
In case of non‑microbiologically confirmed infection, this antibacterial or antifungal agent is considered not to be essential 65/156 (41.7)
Another explanation for the lower than expected ADE 
rate could be the strict definition of ADE that was used, 
i.e., ADE applied within the first 3  days of initiation of 
empirical therapy. Previous studies defined timing of 
ADE in various ways, e.g., within 3 or 5  days following 
treatment initiation, or aligned with the timing of micro-
biology results [15, 36, 37, 39–45]. Expanding the ADE 
time-window to 5 and 7  days would have increased the 
ADE rate to 21% and 23%, respectively.
Our pragmatic approach of defining ADE based on the 
intention of the treating clinician to narrow the antimi-
crobial spectrum was a carefully considered decision. 
Until now, there is no consensus regarding the hierarchy 
of antimicrobials and although there have been propos-
als for ranking antimicrobials, for instance within certain 
classes, e.g., beta-lactam antibiotics, this is difficult—if 
not impossible—to apply to all antimicrobials [33, 46]. 
We observed that 91% of the de-escalated beta-lactam 
prescriptions in our dataset complied with the ranking 
developed by Weiss et al. [33]. However, within the ADE 
population, this ranking definition was only applicable in 
31%.
Clinical cure on day 7 in patients following ADE has 
not been studied before. We attempted to control for 
potential confounding and performed multiple sensitivity 
analyses (e.g. adjustment for SOFA day 0, inappropriate 
empirical therapy and MDR colonization) which did not 
significantly affect our results. We have to acknowledge 
however that our data are observational and it is there-
fore impossible to capture all center, physician, patient 
and infection-related factors that may impact both treat-
ment-related decision making and our primary outcome. 
Particular factors related to empirical treatment and 
infection characteristics appeared to facilitate ADE, e.g., 
2 or more empirical agents, adequate empirical prescrip-
tion, effective source control, improving SOFA scores on 
day 3 and the detection of causative pathogens to guide 
ADE. Previous observations indicate that ADE is under-
taken more often in patients with an already favorable 
clinical course, e.g., improving SOFA score, a phenome-
non that was also observed in our study [4]. Early clinical 
improvement may also explain the shorter lengths of stay 
which we observed in ADE patients compared to patients 
with no treatment change, a finding that has been incon-
sistently documented in previous studies and is in con-
tradiction with the results of Leone et  al. [4, 15, 34, 37, 
39–41, 44]. In contrast to several studies in the literature, 
we found no difference in mortality between the ADE 
and “no change” patients [4, 13, 14]. Again, it is gener-
ally assumed that ADE is typically performed in patients 
who are improving or have a good prognosis; therefore, 
the survival advantage reported in the literature cannot 
be considered a direct causal effect.
The impact of ADE on MDR emergence has been 
investigated sparsely and no study has found an asso-
ciation between ADE and MDR occurrence in either 
direction [15, 34, 41, 44]. We could not demonstrate any 
difference in the emergence of MDR pathogens following 
ADE; however, our study was not designed to make firm 
conclusions about this aspect.
The strengths of the study include the number of 
patients and the global perspective. With data of 152 
centers worldwide, we provide a detailed picture of the 
practice of ADE as a stewardship intervention in real-life 
situations.
The limitations of the study are the heterogeneous 
patient population in terms of geography, types of infec-
tions and methods of antimicrobial stewardship. In addi-
tion, individual centers only included a limited number of 
patients over a short-time period. Details on the reasons 
for not performing ADE were not collected in a prospec-
tive way; as such, an explanation for the observed low 
ADE rate cannot be given. Study design was complicated 
by the lack of a universally accepted ADE definition. The 
low quality of evidence supporting the recent ESICM/
ESCMID consensus definition of ADE underlines the 
ongoing controversy [7]. Our definition was reached by 
consensus and intended to capture real-world practices. 
As mentioned earlier, expanding the ADE time window 
to 5 or 7  days would have increased the ADE rate. A 
priori sample size calculations were complicated by the 
lack of clinical cure rates in the literature and by the fact 
that standard sample size formulas do not readily apply 
to observational analyses that adjust for confounding. 
Our post hoc analyses, however, may be informative for 
the planning of future studies, either observational or 
randomized. Maximal efforts were undertaken to reduce 
bias by using appropriate statistical methods in terms 
of target trial emulation. However, it was not possible 
to determine the exact time when the treating clinicians 
received information about causative microbiology and 
acted upon this. Therefore, we made the assumption that 
this information was available from day 2. Similarly, sus-
ceptibility patterns of the causative pathogens could not 
be included in the outcome analysis. Considering the 
aforementioned reasons, residual confounding may exist. 
Finally, clinical cure was evaluated quite early in the clini-
cal course of the ICU patient (day 7) and our analyses do 
not permit any statements regarding other important 
outcome measures such as, e.g., infection relapse.
In conclusion, this study showed that ADE within 
the first 3  days following empirical antimicrobial ther-
apy for suspected bacterial infection in the ICU is only 
applied in 16% of patients. Our observational effect esti-
mate of ADE—as it was applied and defined in the study 
population—on clinical cure suggested that ADE was not 
worse compared with no-ADE. As ADE was mainly per-
formed in patients who were improving clinically, resid-
ual confounding by unmeasured factors cannot be ruled 
out.
Concerted efforts based on specific patient, infection 
and microbiology-related data and guided by an antimi-
crobial stewardship team are likely needed to promote 
ADE. Further research focusing on antimicrobial pre-
scribing behavior is however required to elucidate barri-
ers to ADE.
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